Long covid sits at the center of this dementia and brain health question.
When standard treatments fall short for Long COVID, doctors are turning to a growing — and often experimental — toolkit of medications that includes low-dose naltrexone, antivirals like Paxlovid, anticoagulants, and drugs originally developed for other conditions entirely. There is no single FDA-approved medication specifically for Long COVID as of recent reports, which means clinicians are borrowing from rheumatology, cardiology, neurology, and even mast cell disorder protocols to address the constellation of symptoms their patients face. For someone like a 58-year-old former teacher who developed debilitating brain fog, fatigue, and autonomic dysfunction after a mild COVID infection, the medication journey might involve cycling through multiple drug classes before finding partial relief — a reality that frustrates patients and physicians alike.
This matters especially for readers concerned about brain health and dementia, because Long COVID’s neurological symptoms — cognitive impairment, memory lapses, difficulty concentrating — overlap uncomfortably with early neurodegenerative conditions. Some researchers have raised concerns that persistent neuroinflammation from Long COVID could accelerate cognitive decline in vulnerable populations, particularly older adults. This article covers the specific drugs doctors are prescribing off-label, which ones show early promise for neurological symptoms, the risks of each approach, and how to have a productive conversation with your doctor when nothing seems to be working.
Table of Contents
- What Medications Are Doctors Trying for Long COVID When Standard Treatments Fail?
- How Long COVID Medications Target Neurological Symptoms and Brain Fog
- The Connection Between Long COVID, Cognitive Decline, and Dementia Risk
- How to Work with Your Doctor on Off-Label Long COVID Treatments
- Risks, Side Effects, and Limitations of Experimental Long COVID Drugs
- Supplements and Non-Prescription Approaches That May Complement Medication
- Where Long COVID Treatment Is Headed
- Conclusion
- Frequently Asked Questions
What Medications Are Doctors Trying for Long COVID When Standard Treatments Fail?
The pharmacological approach to Long COVID has evolved into several distinct categories, each targeting a different hypothesized mechanism of the disease. Anti-inflammatory and immune-modulating drugs represent one major track: low-dose naltrexone, typically prescribed at 1 to 4.5 milligrams, has gained significant grassroots attention and some clinical interest for its potential to reduce neuroinflammation and modulate the immune system. Originally approved at much higher doses for opioid and alcohol use disorders, low-dose naltrexone is thought to temporarily block opioid receptors in a way that triggers the body to upregulate its own endorphin production and dampen overactive immune responses. Several small studies and patient-reported outcomes have suggested improvements in fatigue and cognitive symptoms, though large-scale randomized controlled trials were still underway or in early stages as of recent reports. Another category involves antivirals, most notably extended or repeated courses of nirmatrelvir-ritonavir, marketed as Paxlovid. The rationale here is the viral persistence theory — the idea that fragments of SARS-CoV-2, or even replicating virus, may linger in tissue reservoirs long after the acute infection resolves. Some Long COVID clinics have experimented with longer courses of Paxlovid than the standard five-day acute treatment, and a federally funded clinical trial called STOP-PASC investigated this approach.
Early results from that trial were mixed, showing modest improvements in some symptom measures but not the clear-cut benefit many had hoped for. The anticoagulant approach targets another mechanism: microclotting. doctors in South Africa and Europe pioneered so-called triple anticoagulant therapy — combining aspirin, clopidogrel, and a direct oral anticoagulant — based on research showing abnormal fibrin clots in Long COVID patients’ blood. However, this approach carries real bleeding risks and remains controversial in mainstream medicine. A third track focuses on mast cell stabilizers and antihistamines. Many Long COVID patients report symptoms consistent with mast cell activation syndrome, including flushing, hives, gastrointestinal distress, and histamine intolerance. Over-the-counter antihistamines like famotidine and cetirizine, combined with mast cell stabilizers such as cromolyn sodium or ketotifen, have become a common empiric treatment. While evidence remains largely anecdotal and based on case series, some patients report meaningful symptom reduction, particularly in the gastrointestinal and autonomic categories.
How Long COVID Medications Target Neurological Symptoms and Brain Fog
For patients whose primary Long COVID burden is cognitive — the cluster often called “brain fog” — medication selection becomes particularly nuanced. Brain fog in Long COVID is not a single problem but likely results from multiple overlapping mechanisms: neuroinflammation, impaired cerebral blood flow, autoantibodies targeting neural tissue, and disrupted neurotransmitter signaling. This means a drug that helps one patient’s cognitive symptoms may do nothing for another’s, because the underlying driver differs. Low-dose naltrexone, mentioned earlier, is one of the more commonly tried options for neurological symptoms specifically, with some clinicians reporting that patients notice improved mental clarity within weeks of starting treatment. Guanfacine, an alpha-2 adrenergic agonist originally used for ADHD and high blood pressure, has emerged as another option for Long COVID brain fog after researchers at Yale published a case series showing cognitive improvements. The hypothesis is that guanfacine strengthens prefrontal cortex connectivity, which may be disrupted by neuroinflammation.
However, it is not effective for everyone, and side effects including low blood pressure, dizziness, and sedation can be problematic — particularly for older adults who may already be on blood pressure medications or who are at higher fall risk. If you are over 65 or have existing cardiovascular concerns, this is a medication that requires careful monitoring and dose titration, not something to pursue casually based on an article you read online. Stimulant medications, including those used for ADHD, have also been tried in some Long COVID clinics, though this remains one of the more debated approaches. Some physicians argue that if the cognitive impairment looks functionally like attention deficit, treating it symptomatically with low-dose stimulants is reasonable. Others counter that stimulants may mask symptoms without addressing the root cause, and that in patients with autonomic dysfunction or elevated heart rates — common in Long COVID — stimulants could worsen tachycardia and anxiety. The honest answer is that there is not yet enough clinical trial data to know which cognitive approach works best for which patients, and much of what is being done falls into the category of informed clinical judgment rather than evidence-based protocol.
The Connection Between Long COVID, Cognitive Decline, and Dementia Risk
The overlap between Long COVID cognitive symptoms and early dementia signs is a source of genuine concern among neurologists and researchers. Several large observational studies have found that people who had COVID-19 — even mild cases — showed a statistically higher incidence of new cognitive diagnoses in the year or two following infection compared to matched controls. One widely cited study from the U.S. Department of Veterans Affairs, published in Nature Medicine, found elevated risks of memory problems, Alzheimer’s disease diagnoses, and other neurocognitive issues in the post-COVID period. This does not mean COVID causes Alzheimer’s, but it raises the possibility that the infection may accelerate processes already underway in vulnerable brains. For older adults already managing mild cognitive impairment or early-stage dementia, a Long COVID episode introduces a cruel compounding effect.
The neuroinflammation, potential vascular damage, and immune dysregulation from Long COVID may worsen existing cognitive vulnerabilities. A 72-year-old with mild cognitive impairment who then develops Long COVID brain fog faces a diagnostic challenge: is the worsened cognition from the Long COVID, from the progression of the underlying condition, or both? This distinction matters for treatment decisions, because some Long COVID-specific interventions might help reverse the COVID-related component even if the underlying neurodegenerative process continues. Neuropsychological testing before and after COVID, when available, can help tease apart these contributions. Researchers are also investigating whether certain Long COVID treatments might have neuroprotective properties beyond just symptom relief. Fluvoxamine, an SSRI that gained attention early in the pandemic for its potential anti-inflammatory effects via the sigma-1 receptor, is one such candidate. Some scientists hypothesize that sigma-1 receptor agonism could protect against neurodegeneration, though this remains firmly in the theoretical and early-research stage. The broader point is that treating Long COVID’s neurological dimensions aggressively may not just improve quality of life today — it may matter for long-term brain health trajectories, a concept that should motivate both patients and physicians to take these symptoms seriously rather than adopting a wait-and-see posture.
How to Work with Your Doctor on Off-Label Long COVID Treatments
Navigating off-label medication use for Long COVID requires a different kind of doctor-patient relationship than most people are accustomed to. Because there is no FDA-approved Long COVID drug and no consensus treatment algorithm, the typical dynamic — doctor diagnoses condition, prescribes established treatment — does not apply. Instead, treatment often involves shared decision-making, where the physician brings clinical knowledge and the patient brings detailed symptom tracking and sometimes research they have found through patient communities. This can be productive, but it can also create tension, especially when patients arrive with treatment requests their doctors are unfamiliar with or uncomfortable prescribing. The practical tradeoff is between seeking care at a specialized Long COVID clinic versus working with your existing primary care physician. Long COVID clinics, which have been established at many academic medical centers, typically have more experience with the full range of experimental treatments and may have access to clinical trials.
However, they often have months-long waitlists, may not accept all insurance plans, and can be geographically inaccessible for rural patients. A primary care doctor, by contrast, is accessible and knows your full medical history — critical context when considering drugs that interact with existing medications — but may be reluctant to prescribe treatments they have not seen validated in major guidelines. One useful strategy is to ask your primary care physician to consult informally with a Long COVID specialist or to refer to published treatment frameworks from organizations like the American Academy of Physical Medicine and Rehabilitation, which has issued consensus guidance documents on Long COVID management. Keeping a detailed symptom diary is not just helpful — it is essential for making medication trials interpretable. Track your cognitive symptoms, energy levels, sleep quality, heart rate, and any new symptoms daily, ideally starting before a new medication begins. Without this baseline, neither you nor your doctor can determine whether a drug is actually helping or whether improvement is coincidental. Many patients cycle through several medications over months, and without systematic tracking, the entire process devolves into guesswork.
Risks, Side Effects, and Limitations of Experimental Long COVID Drugs
The most important limitation to acknowledge is that nearly every medication being used for Long COVID is being used off-label, meaning the evidence base is thin compared to what we normally expect before prescribing a drug. Off-label prescribing is legal and common in medicine — it accounts for a significant percentage of all prescriptions in the United States — but it means you are, to some degree, participating in an uncontrolled experiment. The safety profiles of these drugs are generally well-established for their approved uses, but how they behave in the specific biological context of Long COVID is less well understood. Drug interactions represent a particularly acute concern for older adults managing Long COVID alongside other conditions. Paxlovid, for example, is a potent inhibitor of the CYP3A4 enzyme, which means it interacts dangerously with a long list of common medications including certain statins, blood thinners, and heart rhythm drugs. An older patient on rivaroxaban for atrial fibrillation cannot simply add a course of Paxlovid without careful medical supervision.
Similarly, the triple anticoagulant approach to treating microclots is inherently risky in anyone already on blood thinners, and catastrophically so if not managed by a hematologist familiar with the protocol. There is also the risk of false hope and financial exploitation. The desperation of Long COVID patients has created a market for unproven treatments, IV infusions, and supplement stacks promoted on social media and by cash-pay clinics. Some of these may be harmless but expensive; others may be actively dangerous. A warning worth stating plainly: any clinic that guarantees results, charges thousands of dollars out of pocket, or refuses to share their protocols with your other doctors should be approached with extreme skepticism. Legitimate experimental medicine is transparent about uncertainty.
Supplements and Non-Prescription Approaches That May Complement Medication
While not medications in the traditional sense, several supplements have gained traction in Long COVID management and deserve mention because patients frequently use them alongside prescription drugs. Nattokinase, a fibrinolytic enzyme derived from fermented soybeans, has attracted attention for its potential to address microclotting, though clinical trial evidence specific to Long COVID is limited. Coenzyme Q10 and nicotinamide riboside, both involved in mitochondrial energy production, are used by patients reporting severe fatigue, with the rationale that Long COVID may impair cellular energy metabolism.
A clinical trial called RECLAIM tested a combination supplement approach and found some evidence of benefit, though results should be interpreted cautiously. The critical point for readers managing both Long COVID and cognitive concerns is that supplements are not automatically safe, especially in combination with prescription medications. Nattokinase, for instance, has anticoagulant properties that could compound the effects of blood thinners. Any supplement regimen should be disclosed to your prescribing physician, not treated as a separate, parallel track of self-care.
Where Long COVID Treatment Is Headed
The research pipeline for Long COVID treatments, while slower than many patients would like, is more active than at any previous point. Large federally funded trials in the United States and United Kingdom have been investigating antivirals, immunomodulators, and other approaches in rigorous, placebo-controlled formats. The RECOVER initiative, funded by the National Institutes of Health, represents one of the largest coordinated Long COVID research efforts globally, though it has faced criticism for its pace and initial study design choices.
As of recent reports, results from several RECOVER treatment trials were expected or had begun to be released, which could significantly shift the treatment landscape. For the brain health community specifically, the most promising development may be the growing recognition that Long COVID’s neurological effects deserve dedicated research rather than being lumped in with general fatigue and malaise. Specialized neuro-Long-COVID studies examining biomarkers, brain imaging changes, and targeted neurological treatments could yield the kind of specific, actionable guidance that is currently lacking. In the meantime, the best available approach remains a methodical, closely monitored trial of available therapies in partnership with a knowledgeable physician — not a glamorous answer, but an honest one.
Conclusion
Long COVID medication remains a field defined more by clinical experimentation than by established protocols. The drugs doctors are trying — low-dose naltrexone, antivirals, anticoagulants, antihistamines, guanfacine, and others — each target different hypothesized mechanisms of the disease, and no single medication works for everyone. For older adults and those concerned about cognitive health, the neurological dimensions of Long COVID are particularly important to address proactively, given emerging evidence that post-COVID neuroinflammation may interact with or accelerate existing vulnerabilities to cognitive decline.
The path forward requires patience, systematic symptom tracking, and a willingness to work collaboratively with medical providers who acknowledge both the seriousness of the condition and the limits of current knowledge. If your current doctor dismisses your symptoms or refuses to consider any off-label approaches, seeking a second opinion — ideally at a Long COVID clinic affiliated with an academic medical center — is a reasonable next step. The evidence base is growing, clinical trials are producing results, and the medical community’s understanding of Long COVID is materially better than it was even a year ago. That trajectory, while cold comfort to someone suffering today, offers legitimate grounds for cautious optimism.
Frequently Asked Questions
Is there an FDA-approved drug specifically for Long COVID?
As of recent reports, no. All medications currently used for Long COVID are prescribed off-label, meaning they are approved for other conditions and are being applied to Long COVID based on emerging research and clinical judgment.
Can Long COVID cause permanent brain damage or increase dementia risk?
Large observational studies have shown elevated rates of cognitive diagnoses following COVID-19 infection, but it is too early to determine whether these effects are permanent or whether they represent an acceleration of preexisting processes. Ongoing research is investigating this question specifically.
Is low-dose naltrexone safe for older adults with Long COVID?
Low-dose naltrexone is generally considered well-tolerated, with common side effects including vivid dreams and mild sleep disturbances. However, it should not be used by anyone taking opioid pain medications, as it will block their effects. As with any off-label treatment, discuss it with your physician before starting.
How long do you need to try a Long COVID medication before knowing if it works?
Most clinicians recommend giving a medication trial at least four to eight weeks before judging efficacy, though some patients report improvements sooner. Systematic symptom tracking during this period is essential for making an informed decision about whether to continue.
Should I stop my existing medications if I start a Long COVID treatment?
Never stop prescribed medications without consulting your doctor. Many Long COVID treatments can be used alongside existing prescriptions, but drug interactions must be carefully evaluated, especially for older adults on multiple medications.
Are Long COVID symptoms that look like dementia actually dementia?
Not necessarily. Long COVID brain fog can mimic early cognitive impairment, but the mechanisms may be different and potentially more reversible. Neuropsychological testing can help distinguish between Long COVID-related cognitive changes and neurodegenerative conditions.
You Might Also Like
- Self-Injecting Your Medication: Why Doctors Say Home Use Is Getting Safer
- The Medication Causing Birth Defects That Doctors Still Prescribe
- The Dog Medication That Humans Are Actually Taking for Pain
For more, see Alzheimer’s Association — caregiving.
